Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 26, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	3,864	2,025	1,245	1,128	2,581	1,599
Market Cap Growth	79.18%	62.59%	10.35%	-56.28%	61.40%	-12.69%
Enterprise Value	3,664	1,812	1,061	1,121	2,589	1,264
Last Close Price	191.39	107.15	71.42	66.80	99.67	64.17
PE Ratio	79.17	-	23.88	-	45.18	-
Forward PE	37.44	53.58	35.07	-	-	33.23
PS Ratio	15.43	12.11	9.48	5.75	10.69	9.78
PB Ratio	3.96	2.44	1.78	1.89	3.14	2.25
P/TBV Ratio	6.30	4.42	4.18	8.11	7.85	-
P/FCF Ratio	126.05	21.26	27.04	8.99	36.86	31.90
P/OCF Ratio	121.49	20.86	25.12	8.19	32.76	29.30
PEG Ratio	-	3.57	2.34	-	-	1.61
EV/Sales Ratio	14.58	10.84	8.08	5.71	10.72	7.73
EV/EBITDA Ratio	58.12	31.11	22.90	27.11	22.09	18.31
EV/EBIT Ratio	127.01	78.73	108.04	369.11	39.07	30.77
EV/FCF Ratio	119.11	19.03	23.04	8.93	36.96	25.22
Debt / Equity Ratio	0.48	0.01	0.01	0.15	0.40	0.64
Debt / EBITDA Ratio	7.02	0.12	0.13	2.09	2.74	6.42
Debt / FCF Ratio	14.66	0.08	0.13	0.70	4.63	9.11
Net Debt / Equity Ratio	-0.22	-0.30	-0.23	-0.21	-0.02	0.06
Net Debt / EBITDA Ratio	-3.39	-4.27	-3.54	-3.00	-0.14	0.66
Net Debt / FCF Ratio	-6.94	-2.61	-3.56	-0.99	-0.24	0.90
Asset Turnover	0.21	0.19	0.17	0.19	0.18	0.11
Inventory Turnover	6.74	1.71	1.88	4.38	3.50	4.20
Quick Ratio	23.66	8.05	12.49	2.50	10.39	4.70
Current Ratio	24.69	8.93	14.15	2.67	11.15	5.00
Return on Equity (ROE)	5.42%	-0.53%	8.29%	-0.74%	9.98%	0.89%
Return on Assets (ROA)	1.48%	1.66%	0.79%	0.18%	3.11%	1.80%
Return on Invested Capital (ROIC)	3.36%	-6.59%	1.64%	-0.07%	8.50%	7.45%
Return on Capital Employed (ROCE)	2.00%	2.50%	1.30%	0.50%	5.30%	3.30%
Earnings Yield	1.25%	-0.20%	4.19%	-2.96%	2.21%	-0.19%
FCF Yield	0.79%	4.70%	3.70%	11.12%	2.71%	3.13%
Buyback Yield / Dilution	-6.20%	-3.00%	-5.27%	2.19%	-2.50%	14.84%

Updated Feb 26, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q